CD8A and neoplasm: CTL-driven responses have long been recognized as central players in anti-tumor immunity and DCs have the unmatched capacity to cross-present exogenous antigens on the major histocompatibility complex (MHC)-I to naïve CD8+ T cells, causing their differentiation into antigen-specific CTLs [26,27].